<img class="lazy" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://cdn.cancerletter.com/media/2021/03/17053004/TCL-logo-horizontal-white.png" alt="" >

Clinical

Letter To The Editor

GOG Sends Rebuttal Letter to Oncolytics Biotech

Drugs & Targets

Accelerated Approval Granted to Venclexta Tablets in CLL

CCL April – NCI CTEP-Approved Trials for the Month of April

Researchers: Radiation After Surgery Benefits Older Patients More than Younger Patients

Study: SBRT Delivers 98.6% Cure Rate at Five-Year Followup

Opdivo-Yervoy Combination Demonstrates Two-Year Survival Rate of 69 Percent

Phase III Farletuzumab Trial Fails to Meet Endpoints in Platinum-Sensitive Disease

Opdivo Extends OS in Phase III Squamous Cell Carcinoma Trial

NCI CTEP-Approved Trials for the Month of March

Two Phase III Anamorelin Trials Show Improved Lean Body Mass